Thus, the next era of immunotherapy will involve the search for safe combinatory anti-cancer agents which do not interfere with the PD-1/PDL-1 or CTLA-4 immunomodulatory mode of action and do not potentiate related toxicities. This evidence concerns the gene CTLA4 and cancer.